Dr. Marcus Graf

Studied biology at the Universities of Regensburg and Edinburgh and received his doctorate in virology at the University Hospital Regensburg. 1999 – 2014 co-founder and COO of GENEART AG. 2006 IPO at the German Stock Exchange Frankfurt, 2010 Trade Sale of GENEART AG to Life Technologies/Thermo Fisher Scientific. 2014-2022 Managing Director and Site Leader of TFS Geneart GmbH with global responsibility for teams in USA, Japan and UK. Member of the Supervisory Board of Biogents AG and biosecurity expert for NTI/IBBIS. Since 2023 Head of the Center for Research and Transfer (ZFT) at OTH Regensburg.